IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd EBIT Margin for the year ending December 31, 2023: -482.38%

IceCure Medical Ltd EBIT Margin is -482.38% for the year ending December 31, 2023, a 11.10% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

IceCure Medical Ltd EBIT Margin for the year ending December 31, 2022 was -542.59%, a -130.90% change year over year.
IceCure Medical Ltd EBIT Margin for the year ending December 31, 2021 was -234.99%, a -131.73% change year over year.
IceCure Medical Ltd EBIT Margin for the year ending December 31, 2020 was -101.41%, a 64.62% change year over year.
IceCure Medical Ltd EBIT Margin for the year ending December 31, 2019 was -286.62%, a 11.02% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years